Summit Therapeutics (SMMT) Net Cash Flow (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Net Cash Flow data on file, last reported at $312.8 million in Q2 2026.

• Quarterly Net Cash Flow rose 262.57% year-over-year to $312.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $121.5 million (down 54.89% YoY) and the FY2025 annual result came in at $120.3 million, up 256.11% from the prior year.
• Net Cash Flow rose to $312.8 million in Q2 2026, from -$118.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $525.3 million in Q4 2022 to a low of -$578.1 million in Q1 2023.
• A 5-year average of $19.3 million and a median of -$2.0 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow jumped 6634.72% — and 2023, when it sank 10024.15%.
• Tracing SMMT's Net Cash Flow over 5 years: stood at $525.3 million in 2022, then tumbled by 90.98% to $47.4 million in 2023, then tumbled by 76.36% to $11.2 million in 2024, then sank by 218.55% to -$13.3 million in 2025, then surged by 2456.86% to $312.8 million in 2026.
• The last three Net Cash Flow figures came in at $312.8 million (Q2 2026), -$118.7 million (Q1 2026), and -$13.3 million (Q4 2025), per Business Quant data.